Wavelength-Pharmaceuticals-Insert
X

Find Oncology Drugs in Phase III Clinical Development in FINLAND

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothBegin the journey of your innovative API with Fermion.

            Contact the Supplier

            Lead Product(s): Darolutamide

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            Darolutamide significantly reduced risk of death by 31 percent in men with non-metastatic castration-resistant prostate cancer (nmCRPC).

            Virtual BoothBegin the journey of your innovative API with Fermion.

            Contact the Supplier

            Lead Product(s): Darolutamide

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 31, 2020

            Details:

            The CHMP recommendation is based on the results of the Phase III ARAMIS trial evaluating darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT.